![]() Enhertu improves survival for metastatic "HER2-low" breast cancer. Radiation for breast cancer.ĪstraZeneca Canada Inc. Chemotherapy for breast cancer.Īmerican Cancer Society. The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)-status to HER2-low, defined as HER2 expression of 1+ by immunohistochemistry (IHC) or 2+ by IHC without gene amplification, has made a major impact in the field of oncology. Enhertu may be preferred therapy for some metastatic breast cancers.Ĭancer Research UK. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. Modi S, Jacot W, Yamashita T, DESTINY-Breast04 Trial Investigators, et al. Chemotherapy for breast cancer.Īmerican Cancer Society. FDA approves first targeted therapy for HER2-low breast cancer.Īmerican Cancer Society. In certain cancers, especially breast cancer, the HER2 gene mutates (changes) and makes extra. Genes are the basic units of heredity, passed down from your mother and father. It is a gene that makes a protein found on the surface of all breast cells. In assessing pCR in relation to EFS, analysis was performed on 43 independent patient cohorts, which clearly illustrated pCR as an informative predictor of enhanced EFS (HR 0.67, 95 per cent c.i. Targeted approaches to HER2-low breast cancer: current practice and future directions. HER2 stands for human epidermal growth factor receptor 2. The present study is the first to evaluate the estimated survival advantage to achieving pCR specific to EFS, RFS, and OS in HER2 + breast cancer. Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: a multicenter, randomized controlled phase II trial. In the control group, 18 patients (55%) were older than 50, 15 patients (45%) were 50 or younger 30 patients (91%) showed a tumor size of >2 cm, 3 patients (9%) ≤2 cm 21 patients (64%) had about 1 to 2 positive nodes, 9 (27%) had about 3 to 4 positive nodes, and 3 (9%) were node negative and 17 patients (52%) had negative HR status, 16 patients (48%) reported positive. Their hypothesis proved true with the total pCR rate in the treatment group measuring 71.4% (15/21) versus 36.7% (11/30) in the control group a significant difference was found between the 2 groups ( P 2 cm, 5 patients (15%) ≤2 cm 22 patients (64%) had about 1 to 2 positive lymph nodes, 6 (18%) had about 3 to 4, and 6 (18%) were node negative and 21 patients (62%) had a negative hormone receptor (HR) status, while 13 patients (38%) were positive for HR. Investigators hypothesized that patients treated in the investigational group (pyrotinib+TCbH) could have a higher pCR rate than the control group (TCbH). Secondary end points included toxicity, event-free survival, disease-free survival, distant disease-free survival, and objective response rate (ORR).įrom 2019 to 2021, 67 patients with HER2-positive breast cancer were randomized equally into the treatment and control groups. ![]() pCR, the primary end point, was defined in the study as no invasive or in situ disease in the breast or axilla. The randomized, double-blind multicenter study evaluated the efficacy and safety of the addition of pyrotinib, an irreversible second-generation HER2-targeted tyrosine kinase inhibitor (TKI), to TCbH versus TCbH alone given as neoadjuvant treatment in patients with stage II-III HER2-positive breast cancer and invasive carcinoma. “In this study, TCbH plus pyrotinib neoadjuvant therapy significantly improved the total pCR rate of HER2-positive breast cancer patients for about twice TCbH with a manageable safety ,” the study authors, led by Xiaowen Ding, MD, of the Department of Breast Surgery, Zhejiang Cancer Hospital in Hangzhou, China, wrote in their poster. The combination of pyrotinib plus trastuzumab (Herceptin), docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response (pCR) rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer, according to data from a phase 2 trial (NCT03756064) presented during the 2021 ASCO Annual Meeting. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |